← All trials
NCT03071172
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2017
- Primary completion
- Dec 1, 2017
- Completion date
- May 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 252
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- GeneScience Pharmaceuticals Co., Ltd.Lead sponsor
- Peking UniversityOverall official - principal investigator
- Nanjing Medical UniversityCollaborator
- Peking UniversityCollaborator
- Zhejiang UniversityCollaborator
- Central South UniversityCollaborator
- Anhui College of Traditional Chinese MedicineCollaborator
- Sun Yat-Sen UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.